Co-delivery doxorubicin and silybin for anti-hepatoma via enhanced oral hepatic-targeted efficiency

Ying Li, Dandan Yang, Yian Wang, Zhan Li, Chunyan Zhu Drug Delivery Research Center, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100193, People’s Republic of China Background: To establish the combination of doxorub...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Li Y, Yang D, Wang Y, Li Z, Zhu C
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Doxorubicin hydrochloride Silybin Hepatic targeting via oral administration Cholic acid transporter Anti-hepatoma Biodistribution in vivo Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/ea48108eafa8459e8410c0fda7ab82fb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ea48108eafa8459e8410c0fda7ab82fb
record_format	dspace
spelling	oai:doaj.org-article:ea48108eafa8459e8410c0fda7ab82fb2021-12-02T07:44:35ZCo-delivery doxorubicin and silybin for anti-hepatoma via enhanced oral hepatic-targeted efficiency1178-2013https://doaj.org/article/ea48108eafa8459e8410c0fda7ab82fb2018-12-01T00:00:00Zhttps://www.dovepress.com/co-delivery-doxorubicin-and-silybin-for-anti-hepatoma-via-enhanced-ora-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Ying Li, Dandan Yang, Yian Wang, Zhan Li, Chunyan Zhu Drug Delivery Research Center, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100193, People’s Republic of China Background: To establish the combination of doxorubicin (DOX) and silybin (SLB) in oral hepatic-targeting liposomes with the goal of reducing cardiotoxic side effects and improve oral hepatoma treatment. Methods: Distearoylphosphatidylethanolamine–polyethylene glycol–cholic acid-modified liposomes (CA-LP) were used to encapsulate DOX and SLB (CA-LP–DOX/SLB), and the hepatic targeting, efficacy against hepatoma and cardioprotective effects were evaluated by cell toxicity, scratch and apoptosis in vitro studies, and pharmacokinetics and pharmacodynamics in vivo studies. Results: In vitro cell studies showed that CA-LP–DOX/SLB inhibited HepG2 cell proliferation and HCC97H cell migration, and protected H9c2 cells. In vivo pharmacokinetics demonstrated that the CA-LP–DOX/SLB-treated group showed higher liver accumulation and lower heart accumulation of DOX relative to those in the CA-LP–DOX and LP–DOX-treated groups. In vivo pharmacodynamic studies showed that the CA-LP–DOX/SLB-treated group not only efficiently inhibited growth but also induced significantly less tissue damage than that observed in the CA-LP–DOX-treated group. Conclusion: Concurrent administration of DOX and SLB via CA-LP provided a viable strategy to mitigate acute DOX-induced cardiotoxicity. Keywords: doxorubicin, silybin, hepatic targeting via oral administration, cholic acid transporter, anti-hepatoma, biodistribution in vivoLi YYang DWang YLi ZZhu CDove Medical PressarticleDoxorubicin hydrochlorideSilybinHepatic targeting via oral administrationCholic acid transporterAnti-hepatomaBiodistribution in vivoMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 14, Pp 301-315 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Doxorubicin hydrochloride Silybin Hepatic targeting via oral administration Cholic acid transporter Anti-hepatoma Biodistribution in vivo Medicine (General) R5-920
spellingShingle	Doxorubicin hydrochloride Silybin Hepatic targeting via oral administration Cholic acid transporter Anti-hepatoma Biodistribution in vivo Medicine (General) R5-920 Li Y Yang D Wang Y Li Z Zhu C Co-delivery doxorubicin and silybin for anti-hepatoma via enhanced oral hepatic-targeted efficiency
description	Ying Li, Dandan Yang, Yian Wang, Zhan Li, Chunyan Zhu Drug Delivery Research Center, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100193, People’s Republic of China Background: To establish the combination of doxorubicin (DOX) and silybin (SLB) in oral hepatic-targeting liposomes with the goal of reducing cardiotoxic side effects and improve oral hepatoma treatment. Methods: Distearoylphosphatidylethanolamine–polyethylene glycol–cholic acid-modified liposomes (CA-LP) were used to encapsulate DOX and SLB (CA-LP–DOX/SLB), and the hepatic targeting, efficacy against hepatoma and cardioprotective effects were evaluated by cell toxicity, scratch and apoptosis in vitro studies, and pharmacokinetics and pharmacodynamics in vivo studies. Results: In vitro cell studies showed that CA-LP–DOX/SLB inhibited HepG2 cell proliferation and HCC97H cell migration, and protected H9c2 cells. In vivo pharmacokinetics demonstrated that the CA-LP–DOX/SLB-treated group showed higher liver accumulation and lower heart accumulation of DOX relative to those in the CA-LP–DOX and LP–DOX-treated groups. In vivo pharmacodynamic studies showed that the CA-LP–DOX/SLB-treated group not only efficiently inhibited growth but also induced significantly less tissue damage than that observed in the CA-LP–DOX-treated group. Conclusion: Concurrent administration of DOX and SLB via CA-LP provided a viable strategy to mitigate acute DOX-induced cardiotoxicity. Keywords: doxorubicin, silybin, hepatic targeting via oral administration, cholic acid transporter, anti-hepatoma, biodistribution in vivo
format	article
author	Li Y Yang D Wang Y Li Z Zhu C
author_facet	Li Y Yang D Wang Y Li Z Zhu C
author_sort	Li Y
title	Co-delivery doxorubicin and silybin for anti-hepatoma via enhanced oral hepatic-targeted efficiency
title_short	Co-delivery doxorubicin and silybin for anti-hepatoma via enhanced oral hepatic-targeted efficiency
title_full	Co-delivery doxorubicin and silybin for anti-hepatoma via enhanced oral hepatic-targeted efficiency
title_fullStr	Co-delivery doxorubicin and silybin for anti-hepatoma via enhanced oral hepatic-targeted efficiency
title_full_unstemmed	Co-delivery doxorubicin and silybin for anti-hepatoma via enhanced oral hepatic-targeted efficiency
title_sort	co-delivery doxorubicin and silybin for anti-hepatoma via enhanced oral hepatic-targeted efficiency
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/ea48108eafa8459e8410c0fda7ab82fb
work_keys_str_mv	AT liy codeliverydoxorubicinandsilybinforantihepatomaviaenhancedoralhepatictargetedefficiency AT yangd codeliverydoxorubicinandsilybinforantihepatomaviaenhancedoralhepatictargetedefficiency AT wangy codeliverydoxorubicinandsilybinforantihepatomaviaenhancedoralhepatictargetedefficiency AT liz codeliverydoxorubicinandsilybinforantihepatomaviaenhancedoralhepatictargetedefficiency AT zhuc codeliverydoxorubicinandsilybinforantihepatomaviaenhancedoralhepatictargetedefficiency
_version_	1718399253471035392

Co-delivery doxorubicin and silybin for anti-hepatoma via enhanced oral hepatic-targeted efficiency

Ejemplares similares